Hansa Biopharma reports positive efficacy and safety results from Idefirix® European post authorization study in kidney transplantation

Contributed by: PR Newswire

Tags

HANSA-BioPhrma

More Like This

Hansa Biopharma completes enrolment in European Phase 3 20-HMedIdeS-19 Post Authorization Efficacy and Safety study in highly sensitized kidney transplant patients

Hansa Biopharma announces first commercial kidney transplant patient treated with Idefirix in Australia

SERB Pharmaceuticals to acquire European and MENA rights to Idefirix® (imlifidase) from Hansa Biopharma for €115 million

Hansa Biopharma presents positive outcomes of five-year follow-up study of imlifidase in kidney transplantation at ESOT Congress 2025 in London

Hansa Biopharma announces closing of €115 million licensing transaction with SERB Pharmaceuticals for Idefirix in Europe and MENA

Imlifidase demonstrated 90% patient survival and 82% graft survival at five years in extended pooled analysis with data from 17-HMedIdeS-14 study

SERB Pharmaceuticals Completes Acquisition of European and MENA Rights to Idefirix® (imlifidase) from Hansa Biopharma

Imlifidase successfully meets primary endpoint in pivotal US Phase 3 ConfIdeS trial in kidney transplantation